Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

BACKGROUND: Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve ease of administration. With knowledge of nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., Bello, A., Roy, A., Agrawal, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834087/
https://www.ncbi.nlm.nih.gov/pubmed/28520840
http://dx.doi.org/10.1093/annonc/mdx235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834087/
https://www.ncbi.nlm.nih.gov/pubmed/28520840
http://dx.doi.org/10.1093/annonc/mdx235

Ejemplares similares